Notably, PC3 cells, the more aggressive prostate cancer model, retained an expression profile consistent with their malignant phenotype, characterized by BCL-2 overexpression, PTEN downregulation, and increased expression of the inflammation-related gene IL-6. This evidence concerns the gene BCL2 and prostate carcinoma.